Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Fuhr

Showing results (31-40 of 136) with videos related to

Pageof 14
Sort By:
Therapeutic Advances in Urology|July 28, 2017
Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndromeDominik Dahlinger, Sevinc Aslan, Markus Pietsch, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2018
Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract InfectionsMax Taubert, Mark Lückermann, Andreas Vente, et al.
European Journal of Clinical Pharmacology|August 16, 2008
Mesalazine pharmacokinetics and NAT2 phenotypeHendrik Lück, Martina Kinzig, Alexander Jetter, et al.
Clinical Pharmacokinetics|June 6, 2013
Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamideWilli Cawello, Uwe Fuhr, Ursula Hering, et al.
Toxicology Mechanisms and Methods|May 21, 2013
The effect of organic solvents on enzyme kinetic parameters of human CYP3A4 and CYP1A2 in vitroDennis Rokitta, Kay Pfeiffer, Christina Streich, et al.
European Journal of Clinical Pharmacology|October 10, 2022
A population pharmacokinetic model for creatinine with and without ingestion of a cooked meat mealZhendong Chen, Chunli Chen, Max Taubert, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|May 8, 2019
A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposureSami Ullah, Peter Matzneller, Markus Zeitlinger, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 24, 2012
Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarkerFriederike Kanefendt, Andreas Lindauer, Klaus Mross, et al.
Planta Medica|October 31, 2007
The effect of silymarin on oral nifedipine pharmacokineticsUwe Fuhr, Svane Beckmann-Knopp, Alexander Jetter, et al.
European Journal of Clinical Pharmacology|August 3, 2010
Torsades de pointes tachycardia induced by common cold compound medication containing chlorpheniramineAmir M Nia, Uwe Fuhr, Natig Gassanov, et al.
Pageof 14

Showing results (31-40 of 136) with videos related to

Sort By:
Pageof 14
Therapeutic Advances in Urology|July 28, 2017
Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndromeDominik Dahlinger, Sevinc Aslan, Markus Pietsch, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2018
Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract InfectionsMax Taubert, Mark Lückermann, Andreas Vente, et al.
European Journal of Clinical Pharmacology|August 16, 2008
Mesalazine pharmacokinetics and NAT2 phenotypeHendrik Lück, Martina Kinzig, Alexander Jetter, et al.
Clinical Pharmacokinetics|June 6, 2013
Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamideWilli Cawello, Uwe Fuhr, Ursula Hering, et al.
Toxicology Mechanisms and Methods|May 21, 2013
The effect of organic solvents on enzyme kinetic parameters of human CYP3A4 and CYP1A2 in vitroDennis Rokitta, Kay Pfeiffer, Christina Streich, et al.
European Journal of Clinical Pharmacology|October 10, 2022
A population pharmacokinetic model for creatinine with and without ingestion of a cooked meat mealZhendong Chen, Chunli Chen, Max Taubert, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|May 8, 2019
A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposureSami Ullah, Peter Matzneller, Markus Zeitlinger, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 24, 2012
Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarkerFriederike Kanefendt, Andreas Lindauer, Klaus Mross, et al.
Planta Medica|October 31, 2007
The effect of silymarin on oral nifedipine pharmacokineticsUwe Fuhr, Svane Beckmann-Knopp, Alexander Jetter, et al.
European Journal of Clinical Pharmacology|August 3, 2010
Torsades de pointes tachycardia induced by common cold compound medication containing chlorpheniramineAmir M Nia, Uwe Fuhr, Natig Gassanov, et al.
Pageof 14